Skip to main content

Table 3 Proportion of Clinical Response in the treatment groups

From: A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients

  TA4415V Reference trastuzumab
Complete Response (%) 15.22 23.81
Partial Response (%) 73.91 59.52
Progressive Disease (%) 0.00 2.38
Stable Disease (%) 6.52 9.52
Unassessable (%) 4.35 4.76
  1. Valid percent was reported
  2. P-value = 0.59
  3. P-value for ORR (Overall response includes complete and partial response) = 0.72
  4. P-value computed using fisher exact Test